News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobiotix Reports Final Preclinical Safety Data: Its 'NBTXR3' Nanoparticles Are Designed to Be Safe and Effective Treatment for Radiosensitive and Radioresistant Tumors


7/9/2009 9:23:10 AM

PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company, announced today that preclinical follow-up data regarding long-term toxicity evaluation suggests that its patented NBTXR3 nanoparticles are designed to be a safe and effective treatment for radiosensitive and radioresistant tumors. The preclinical studies were performed at NAMSA Biomatech. NAMSA is registered with the CDER and CBER divisions of the FDA.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES